AstraZeneca
NEWS
It will immediately begin to sell Bylvay to treat patients impacted by PFIC, a rare cholestatic liver disease that often leads to cirrhosis and liver failure within the first ten years of life.
Notably, Koselugo was studied in pediatric populations first, a reversal of the typical development path taken by the majority of drugs.
The company’s technology is designed to attach any off-the-shelf antibody with any payload without the need for modification.
The lawsuit alleges that Ocugen made “materially false and misleading statements” about its operations and compliance policies.
The U.S. appears to be beating back COVID-19 but it’s still raging in many parts of the world, and studies and trials are still ongoing. Here’s a look at some of today’s top COVID-19 stories.
Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity.
This week’s announcement includes a step to the side for CMO Amit Rakhit, who will transition to the biotech’s advisory board.
Continuing studies and news about COVID-19 around the world keeps coming in. Here’s a look.
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.
JOBS
IN THE PRESS